Digitally Enhanced Pulmonary Rehabilitation (DEPR)

Pulmonary Rehabilitation (PR) is a highly effective therapy for Chronic Obstructive Pulmonary Disease (COPD), improving symptoms, exercise capacity and quality of life.

If PR is given in time, 1-year hospital readmission and mortality rates can be reduced by 50% and 40% respectively.

myCOPD addresses a critical challenge around a lack of access to traditional, in person PR classes:

• Currently, only 3% of patients in the US who are eligible
for PR receive it.

• Low resources, staffing and infrastructure and insurance reimbursement has led to only 1 traditional PR center for every 6,030 individuals with COPD.

Increased capacity

Choice of fully remote (myCOPD only) or hybrid (myCOPD plus traditional PR) means that more patients receive treatment.

Increased revenue

DEPR enables physician billing to CMS codes which cannot be accessed for traditional PR.

Lower readmission costs

COPD is the 3rd leading cause of readmission in the US - an increase in PR capacity results in admission savings of between $7,000-$15,000 per patient. 

Lower readmission costs

COPD is the 3rd leading cause of readmission in the US - an increase in PR capacity results in admission savings of between $7,000-$15,000 per patient. 

Trial Evidence.

“As effective as hospital-based programs.”

Global Strategy for the Diagnosis and Management of COPD (GOLD 2023).

"If pulmonary rehabilitation was a medication, IT WOULD BE A BLOCKBUSTER.”

David Mannino, MD, FCCP, FERS Director, Pulmonary Epidemiology University of Kentucky.

"A ‘business in a box’ that drives practice revenue and provides the best possible care for patients that extends lives, and saves lives.”

myCOPD Customer (US Healthcare Provider).

“The tragedy in the US is that [PR] is only available to such a small percentage."

David Mannino, MD, FCCP, FERS Director, Pulmonary Epidemiology University of Kentucky.